CEBPA and acute myeloid leukemia: Patients 10–14 (P10 M/62Y, P11 M/39Y, P12 F/46Y, P13 F/49Y and P14 F/43Y) are acute myeloid leukaemia (AML) patients habouring mono- or bi-allelic CEBPA (NM_004364.5) mutations (see Supplementary Fig. S9 online).